Insulin remains to be a critical therapy for the management of diabetes despite the introduction of novel therapies. A basal and mealtime insulin is often required to achieve glucose control. Insulin is a critical therapy for type 2 diabetes:
Barriers to adherence include;6
Missed insulin doses are common, and an important factor in poor glycemic control. Mealtime doses are especially important, and are often omitted3
CeQur has a platform of simple, wearable, 3-day devices that have been developed to provide the benefits of newer, technologically advanced insulin therapies without their complexity and up-front expense. These devices have been designed to reduce the barriers and challenges of daily insulin injection therapy to enable people to achieve target glycemic control.
* Humalog® is a registered trademark of Eli Lilly and Company. NovoLog® is a registered trademark of Novo Nordisk A/S.